Zai Lab (NASDAQ:ZLAB - Get Free Report) had its target price increased by JPMorgan Chase & Co. from $36.00 to $37.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective points to a potential upside of 69.48% from the stock's current price.
Several other equities research analysts have also issued reports on ZLAB. Wall Street Zen raised shares of Zai Lab from a "sell" rating to a "hold" rating in a research report on Saturday, September 26th. Citigroup upped their price target on shares of Zai Lab from $44.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a report on Tuesday, October 6th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Zai Lab in a research report on Tuesday, October 27th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $38.50.
View Our Latest Report on ZLAB
Zai Lab Price Performance
Zai Lab stock traded down $0.28 during trading hours on Thursday, hitting $21.83. The stock had a trading volume of 356,782 shares, compared to its average volume of 896,562. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of -12.20 and a beta of 0.77. Zai Lab has a 1-year low of $15.96 and a 1-year high of $29.02. The stock's fifty day moving average is $24.46 and its two-hundred day moving average is $21.35.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.18. Zai Lab had a negative return on equity of 31.15% and a negative net margin of 44.91%. The company had revenue of $108.21 million during the quarter, compared to analysts' expectations of $107.90 million. As a group, sell-side analysts anticipate that Zai Lab will post -2.19 EPS for the current year.
Insider Buying and Selling
In other Zai Lab news, Director Richard Gaynor bought 1,228 shares of the stock in a transaction on Tuesday, November 10th. The stock was purchased at an average price of $27.19 per share, for a total transaction of $33,389.32. Following the completion of the purchase, the director directly owned 81,965 shares in the company, valued at approximately $2,228,628.35. This trade represents a 1.52% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.88% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Zai Lab
A number of institutional investors have recently modified their holdings of the business. B Group Inc. bought a new position in shares of Zai Lab during the third quarter valued at approximately $11,870,000. Soleus Capital Management L.P. bought a new stake in shares of Zai Lab in the 3rd quarter worth approximately $40,643,000. Toronto Dominion Bank acquired a new position in Zai Lab during the 3rd quarter valued at approximately $26,193,000. Nantahala Capital Management LLC boosted its position in Zai Lab by 65.0% during the 3rd quarter. Nantahala Capital Management LLC now owns 330,000 shares of the company's stock valued at $8,692,000 after purchasing an additional 130,000 shares during the period. Finally, HighVista Strategies LLC bought a new position in Zai Lab during the 3rd quarter worth $609,000. Institutional investors own 41.65% of the company's stock.
About Zai Lab
(
Get Free Report)
Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab's portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.